Researchers conducted a multicenter study involving 603 patients who were suspected of having a pulmonary embolism. The goal was to see if using a SPECT V/Q-based diagnostic strategy was as effective as other standard methods, such as CTPA and planar V/Q imaging.
The results showed that the diagnosis rates for pulmonary embolism were similar across different testing methods. Specifically, the SPECT V/Q group had a 20.1% diagnosis rate, while the CTPA group had 20.7% and the planar V/Q group had 16.0%. Additionally, the risk of developing other blood clots within three months was very low in all groups.
It is important to note that this study was stopped early due to slow recruitment and funding issues. Because it ended early, the researchers could not officially confirm if SPECT V/Q is equal to standard methods. While the results suggest it could be a reliable alternative for doctors to use, more complete data would be needed to reach a final conclusion.
Common questions
Is SPECT V/Q a reliable way to find a pulmonary embolism?
The study included 603 patients and found that the SPECT V/Q group had a 20.1% diagnosis rate, which was very similar to the 20.7% rate seen in the CTPA group. While it appears to be a reliable alternative, the trial ended early, so it did not officially prove it is equal to standard methods.
What are the risks of using this imaging method?
The study tracked patients for three months and found very low rates of additional blood clots. The risk was 0.5% for those who had SPECT V/Q, 0.0% for those with CTPA, and 0.8% for those with planar V/Q. No specific adverse events were reported during the study.
How does this compare to other tests like CTPA?
The diagnosis rates were very similar between SPECT V/Q (20.1%) and CTPA (20.7%). The risk of new blood clots within three months was also comparable across both methods. Because the study ended early, doctors should still consult current guidelines for standard care.
